Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic  by Francis, Helen C. et al.
Respiratory Medicine (2009) 103, 736e742ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedPrevalence of airflow obstruction in patients
attending a rapid access chest pain clinicHelen C. Francis a,*, Wendy Colecliffe b, Michelle L. Hazell c, Dave Singh d,
Robert Niven d, Gerry W. Hagan e, Michael D. Spencer e,f, Timothy L. Frank ca North West Lung Centre, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK
b Cardiology Unit, Wythenshawe Hospital, Manchester M23 9LT, UK
c GP Research Unit, North West Lung Centre, Wythenshawe Hospital, Manchester M23 9LT, UK
d North West Lung Centre/University of Manchester, Wythenshawe Hospital, Manchester M23 9LT, UK
e Formally of Respiratory Medicine Development Centre, GlaxoSmithKline, Greenford UB6 0HE, UK
f Janssen Cilag, High Wycombe, Buckinghamshire HP12 4EG, UK
Received 30 May 2008; accepted 20 November 2008
Available online 31 December 2008KEYWORDS
Airflow obstruction;
COPD;
IHD;
Co-morbidity* Corresponding author. Tel.: þ44 1
E-mail addresses: Helen.c.francis@
manchester.ac.uk (M.L. Hazell), ds
(G.W. Hagan), mike.spencer@mac.co
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.11.016Summary
Background: Many UK hospitals have set-up specialised chest pain clinics to deal promptly and
efficiently with cases of possible cardiac chest pain. It is possible that a proportion of patients
attending these clinics will have a respiratory cause for their chest pain, or respiratory disease
in addition to their cardiac pain. This study aimed to determine the prevalence of airflow
obstruction, ischaemic heart disease and dual pathology in such patients.
Methods: Spirometry was performed on patients referred to a rapid access chest pain clinic over
a 12-month period (target population of 400 patients). The main outcome measure was the preva-
lence of airflow obstruction (defined using spirometry), ischaemic heart disease and dual pathology.
Results: 405 subjects participated in the study. Abnormal spirometry was detected in 21% of
patients (nZ 85). Airflow obstruction was the predominant lung function abnormality and was de-
tected in 60 patients. Ischaemic heart disease was diagnosed in 21% of patients (nZ 85). Dual
pathology was found in 4% of patients (nZ 17).
Conclusions: Previous studies have reported a link between impaired lung function and future
cardiovascular morbidity and mortality. This study suggests that airflow obstruction is an important
alternative differential diagnosis in patients referred to a rapid access chest pain clinic. The iden-
tification of abnormal spirometry may help to better risk-stratify patients for future cardiovascular
events and allow interventions to be instituted.
ª 2008 Elsevier Ltd. All rights reserved.61 2912847; fax: þ44 161 2912550.
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Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic 737Introduction example the patient was not able to exercise for a suffi-In order to deal promptly and efficiently with cases of
possible cardiac chest pain, specialised rapid access chest
pain clinics (RACPCs) have been set-up in many hospitals in
the United Kingdom. The evaluation of the patients
referred to these clinics has, however, been almost entirely
devoted to the exclusion of cardiac cause, and investigation
of a non-cardiac cause is rarely undertaken. Both Ischaemic
Heart Disease (IHD) and respiratory diseases such as Chronic
Obstructive Pulmonary Disease (COPD) share smoking as
a common risk factor,1,2 and respiratory disease is another
important cause of chest pain.3
We hypothesised that a proportion of patients attending
such clinics will have a respiratory cause for their chest
pain, or will have respiratory disease in addition to their
cardiac pain, which may be overlooked or remain
untreated. Our study aimed to determine the prevalence of
airflow obstruction (AO), IHD and the co-existence of both
conditions (dual pathology) in patients attending a rapid
access chest pain clinic.
Methods
The study was conducted in accordance with the recom-
mendations found in the Helsinki Declaration of 19754 and
was approved by Wrightington, Wigan and Leigh Research
Ethics Committee.
Subjects were recruited over a 12-month period from
the South Manchester University Hospital Trust rapid access
chest pain clinic (RACPC) and all subjects provided written,
informed consent to participate. As far as we are aware,
rapid access chest pain clinics are unique to the UK and are
defined as a cardiologist-supervised facility for the assess-
ment of patients with recent onset chest pain. Patients who
develop symptoms that their General Practitioners (GPs)
think may be caused by ischaemic heart disease are
referred to the RACPC and should be assessed within two
weeks. This was part of the recommendations made by the
National Service Framework for Coronary Heart Disease5 in
order to ensure that people who develop new symptoms
can be quickly assessed by a specialist. The referral criteria
for the clinic are: recent onset cardiac sounding chest pain
within the previous six weeks, no previous history of
ischaemic heart disease, not previously assessed in outpa-
tients or as an inpatient for chest pain and unstable angina
or myocardial infarction not suspected. Only patients
whose appointment allowed for 24 h consideration of the
consent were allowed to participate. Subjects unable to
complete questionnaires (without assistance), due to
English language proficiency or visual impairment were
excluded.
Standard clinic protocols were followed for assessment
of cardiac cause. Patients had an electrocardiogram (ECG)
performed on arrival in the clinic and were then seen and
assessed by a specialist nurse and cardiologist. A history
and examination were undertaken and an exercise ECG was
performed if appropriate. The exercise testing was carried
out using the Bruce protocol,6 which is widely used to
perform exercise tests. Where patients were unable to
carry out the exercise test, or the test was inconclusive (forcient period of time) additional tests were organised such
as echocardiogram, dobutamine stress echocardiography or
myocardial perfusion scan. Suitable patients who were
thought to have angina were placed on a waiting list for
angiography. All patients who wished to participate in the
study (regardless of their cardiac diagnosis) were then
recruited.
Spirometry testing was then performed according to
American Thoracic Society guidelines (1994 update)7,8 using
a Microlab desktop spirometer (Micro Medical Ltd, Roches-
ter, Kent). European Community for Steel and Coal (ECCS)
predicted values were used and an ethnic correction factor
was applied where appropriate.7,8 Forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/
FVC ratio were determined. Reversibility testing was not
performed as part of this study, hence all values were pre-
bronchodilator. Subjects were classified as having airflow
obstruction using ATS/ERS task force guidelines,9 with AO
being defined as an FEV1/FVC ratio 0.70. In addition,
severity of airflow obstruction was based on FEV1 percent
predicted values: mild AO was defined as FEV1 80% pre-
dicted, moderate AO as FEV1 50e80% predicted, severe
COPD as FEV1 30e50% predicted and very severe AO as FEV1
<30% predicted. Subjects were classified as ‘‘at risk’’ of
COPD if they had normal lung function, but a pack year
smoking history of 20 years or more, or symptoms of cough,
sputum or dyspnoea. Restrictive spirometry defects were
classified as FEV1/FVC ratio 0.70 and FVC <80% predicted.
The results of the spirometry were explained to the
participant and a letter explaining the results, suggesting
treatment and/or further investigation was sent to the
general practitioner.
Wythenshawe Community Asthma Project question-
naire10 and Medical Research Council (MRC) dyspnoea
score11 questionnaires were completed. For the purposes of
the analysis, the MRC scores were categorised as <3 or
3.12
Diagnosis of IHD was obtained from the medical records
after the clinic visit (once results of any further tests
carried out such as angiograms or echocardiograms had
been reported). Diagnosis of airflow obstruction was
determined at the study visit (from spirometry results). The
prevalence of these diseases in patients referred to rapid
access chest pain clinics was determined.
Statistics
Characteristics of the populations with and without AO and
with and without IHD were compared. Categorical variables
were compared using Chi squared tests and continuous
variables were compared using t-tests. All analyses were
carried out using the Statistical Package for the Social
Sciences (SPSS) Version 13.0 for Windows (SPSS Inc., Chi-
cago, IL, USA).
Results
Our target population was patients who attended the
RACPC between 11th February 2005 and 6th February 2006.
Six hundred and seventy patients attended the clinic during
738 H.C. Francis et al.this time, of whom 483 were eligible to take part as they
had received our letter of invitation. Four hundred and five
patients participated in the study. We therefore achieved
a response rate of 84% of the eligible population and 60% of
the total population. 403 patients performed adequate lung
function tests. Characteristics of the patients recruited are
presented in Table 1. The mean age was 56 with a range
21e88 years, with the majority (62.5%, nZ 253) being
current or ex-smokers.
Ischaemic heart disease diagnosis was not available for 4
subjects due to their failure to attend for additional tests
that were required. Eighty-five patients (21%) were diag-
nosed as having ischaemic heart disease. Significantly most
of the patients with either IHD alone or dual pathology were
male (c2Z 10.13; p< 0.001). The prevalence of ischaemic
heart disease in those subjects who were current or ex-
smokers was 22.5%.
Eighty-five subjects (21%) were found to have abnormal
lung function (Table 2). Both restrictive and obstructiveTable 1 Patient characteristics.
Characteristic All patients
(nZ 405)
Neither airflow
obstruction nor
IHD (nZ 272)
Gender n (%)
Male 209 (51.6) 125 (46.0)
Female 196 (48.4) 147 (54.0)
Age in years
Mean
(95% confidence interval)
56.3 (55.1e57.5) 53.7(52.3e55.1)
Smoking status
Current smoker 77 (19.0) 43 (15.8)
Ex-smoker 176 (43.5) 112(41.2)
Never smoked 152 (37.5) 117(43.0)
Pack years history
Median (IQR) 5.4 (22.5) 2.5 (18.0)
History of asthma
n (%) 42 (10.4) 29 (10.7)
History of COPD
n (%) 12 (3.0%) 3 (1.1)
History of hypertension
n (%) 106 (26.7) 64 (23.5)
History of diabetes
n (%) 27 (6.7) 16 (5.9)
FEV1% predicted
Mean
(95% Confidence interval)
93.2 (91.4e94.9) 97.6 (95.9e99.3)
FVC % predicted
Mean
(95% Confidence interval)
98.3 (96.7e99.8) 100.3 (98.6e102.0
FEV1/FVC ratio
Mean
(95% Confidence interval)
0.78 (0.77e0.78) 0.81 (0.80e0.81)patterns were seen. The prevalence of abnormal lung
function in those patients who were current or ex-smokers
was 27.7%. Sixty subjects were classified from spirometry
results as having airflow obstruction. Eighty-eight percent
of subjects with AO were current or ex-smokers (and 86% of
subjects with AO alone were current or ex-smokers).
Twenty-five subjects were identified as having a restrictive
defect. However, two of these subjects had an obstructive
spirometry pattern (reviewed by a respiratory physician),
but were unable to reach FVC and were therefore cat-
egorised as restrictive.
Forty-three subjects (10.6% of entire group) had AO
alone, and 17 subjects (4.2%) had dual pathology. Of the 60
subjects with AO, 7 (11.7%) had a prior history of asthma
and 7 (11.7%) had a previous history of COPD. Thirteen of
the fourteen subjects with a previous history of airflow
obstruction were on treatment with inhaled corticosteroids
and/or bronchodilators. Fifty-four of all the subjects
studied had a prior diagnosis of asthma or COPD, of whichAirflow obstruction
only (nZ 43)
IHD
only (nZ 68)
Dual
pathology (nZ 17)
25 (58.1) 45 (66.2) 12 (70.6)
18 (41.9) 23 (33.8) 5 (29.4)
58.7 (55.3e62.0) 62.9 (60.2e65.5) 68.1 (63.8e72.5)
19 (44.2) 10 (14.7) 4 (23.5)
18 (41.9) 31 (45.6) 12 (70.6)
6 (14.0) 27 (39.7) 1 (5.9)
35 (50.5) 3.0 (17.8) 30 (34.1)
4 (9.3) 5 (7.4) 3 (17.6)
6 (14.0) 2 (2.9) 1 (5.9)
12 (27.9) 25 (36.8) 6 (35.3)
3 (7.0) 5 (7.4) 3 (17.6)
68.5 (62.4e74.6) 96.7 (92.8e100.6) 70.0 (61.1e79.0)
) 89.1 (83.3e94.9) 98.2 (94.6e101.8) 88.8 (80.9e96.7)
0.62 (0.59e0.65) 0.79 (0.78e0.80) 0.62 (0.57e0.67)
Table 2 Spirometry findings.
Number %
Airflow Obstruction (AO) nZ 60
Mild AO [FEV1/FVC 0.70;
FEV1 80% predicted]
17 4.2
Moderate AO [FEV1/FVC 0.70;
FEV1 50e80% predicted]
32 7.9
Severe AO [FEV1/FVC 0.70;
FEV1 30e50% predicted]
8 2.0
Very severe AO [FEV1/FVC 0.70;
FEV1< 30% predicted]
3 0.7
At risk of COPD
(20 pack year smoking history
and symptoms of cough,
sputum or dyspnoea)
51 12.7
Restrictive defect [FEV1/FVC 0.70;
FVC < 80% predicted]
25 6.2
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the spirometric findings for those subjects with and without
a previous diagnosis of airflow obstruction is presented in
Fig. 1.
Descriptive analysis of the data (Table 3) showed that
subjects with airflow obstruction were more likely to have
experienced symptoms of wheeze, phlegm production and
chronic productive cough or phlegm and have an MRC
dyspnoea score of 3 or more. In addition to having signifi-
cantly lower lung function (FEV1 percent predicted, FVC
percent predicted and FEV1/FVC ratio), subjects with AO
were significantly older and had higher smoking pack year
history. The mean age of the subjects with AO was 61 years,
and 4 (7%) of these subjects were over 75 years of age.
Subjects with IHD were more likely to be male and were
significantly older than patients with no IHD (Table 4). The
mean age of the subjects with IHD was 64 years, and 12
(14%) of subjects with IHD were over 75 years of age. TheAll subje
n=40
Prior diagnosis of
airflow obstruction
n=54
Normal
Spirometry
n=37
Obstructive
Spirometry
n=14
Restrictive
Spirometry
n=3
Figure 1 Spirometry findings and primean FEV1/FVC ratio was lower in those subjects with IHD
compared with no IHD diagnosis.
Discussion
The principal aim of this study was to determine the
prevalence of airflow obstruction, IHD and dual pathology
in patients attending a chest pain cardiology clinic. We
found that a significant proportion of these patients had
abnormal spirometry, with the majority showing evidence
of AO. The same proportion of participants was diagnosed
with IHD as were found to have abnormal spirometry.
The prevalence of ischaemic heart disease detected in
this study was similar to that of a multi-centre study of
patients with chest pain attending RACPCs at six Hospitals
in England.13 In this recent study, angina was diagnosed in
27% of patients.
It is possible that the signs and symptoms of chest pain
may differ between patients with airflow obstruction and
those with ischaemic heart disease. However, we did not
assess this as part of this study as one of the referring
criteria was that the patients should have cardiac sounding
chest pain.
Both obstructive and restrictive spirometry patterns
were seen. Twenty-five subjects were classified as having
a restrictive defect. There is evidence that cardiac
enlargement and heart failure (HF) can result in a restric-
tive lung function pattern, thought to be due to intratho-
racic space limitation impairing the lungs ability to fill.14
However, we have no data for cardiomegaly or HF preva-
lence in our patient population. Obesity is also associated
with restrictive spirometry.15 Nineteen of the twenty-five
(76%) subjects with a restrictive pattern had a BMI in the
overweight (25e29.9) or obese (30) category.
We used an empirical level of 0.70 for FEV1/FVC ratio
(pre-bronchodilator) in order to define airflow obstruction.
Hadwe included reversibility testing in our protocol, wemay
have been better able to differentiate between a diagnosis
of asthma or COPD. However, there was insufficient time
during the clinic sessions to allow two sets of lung functioncts
3
No prior diagnosis of
airflow obstruction
n=349
Normal
Spirometry
n=281
Obstructive
Spirometry
n=46
Restrictive
Spirometry
n=22
or diagnosis of airflow obstruction.
Table 3 descriptive statistics: subjects with evidence of AO compared with no AO.
Categorical variables: n (%) Airflow obstruction No Airflow obstruction p Value for c2 test
Gender 37 (61.7%) male 173 (49.9%) male 0.091
Cough in the last 12 year 39 (65.0%) 168(49.3%) 0.025
Wheeze in the last year 44 (73.3%) 124 (36.4%) <0.001
Phlegm production in the last year 35 (58.3%) 106 (31.2%) <0.001
Chronic productive cough or phlegm 32 (53.3%) 70 (20.6%) <0.001
MRC dyspnoea score of 3 or more 20 (33.3%) 61 (17.8%) 0.006
Continuous variables: mean (95% CI) Airflow obstruction No airflow obstruction p Value for t-test
Age 61.3 (58.5e64.2) 55.5 (54.1e56.8) 0.001
Log transformed pack years 3.3 (3.0e3.6) 2.5 (2.3e2.6) <0.001
FEV1% predicted 68.9 (64.0e73.9) 97.5 (95.9e99.0) <0.001
FVC % predicted 89.0 (84.4e93.6) 100.0 (98.4e101.5) <0.001
FEV1/FVC ratio 61.7 (59.2e64.2) 80.3 (79.7e80.8) <0.001
740 H.C. Francis et al.measurements to be performed. Using a threshold of 0.70 for
FEV1/FVC ratio is widely used to define airways obstruction
16
and has been adopted for simplicity in order to aid uptake of
spirometry as a clinical tool. However, there is the potential
for miss-classification since the FEV1/FVC ratio falls with
increasing age.17e19 This may lead to over-diagnosis in the
elderly and the potential for under-diagnosis in younger
adults.20 Of the sixty subjects identified as having AO, four
(7%) were seventy-five years of age or above. Although
these weaknesses relating to misdiagnosis may have slightly
influenced the total identified prevalence of airflow
obstruction, it is likely that the findings are close to that
which we would have found with more rigorous investiga-
tions (such as including reversibility, lung volumes and
transfer factormeasurements). More complex investigations
would have been impractical to carry out in this study due to
time constraints.
Another limitation of this study relates to the overall
response rate of 60%. We are not able to ascertain the
cardiac or respiratory status of the patients who were not
eligible to take part or refused, which may confound the
results. Very few participants refused to participate (84% of
eligible patients agreed to take part). It was a requirement
of the ethical approval for the study that patients had at
least 24 h (from being provided with the information sheet)
to decide whether or not they wished to take part. In theTable 4 descriptive statistics: Patients with IHD compared with
Categorical variables: n (%) IHD
Gender 57 (67.1%) mal
Cough in the last 12 year 37 (43.5%)
Wheeze in the last year 32 (37.6%)
Phlegm production in the last year 26 (30.6%)
Chronic productive cough or phlegm 20 (23.5%)
MRC dyspnoea score of 3 or more 21 (24.7%)
Continuous variables: mean (SD) IHD
Age 63.9 (61.6e66.2)
Log transformed pack years 2.7 (2.4e3.0)
FEV1% predicted 91.4 (87.1e95.6)
FVC % predicted 96.3 (93.0e99.6)
FEV1/FVC ratio 75.4 (73.4e77.4)majority of cases the reason that patients were not eligible
was that their appointment had been at very short notice,
which did not allow sufficient time for them to receive the
information letter. Since this occurred when the referral
rate slowed down and was related to the availability of
short notice appointments (often arranged by telephone on
the same day as the GP referral had been made) rather than
particular patients being prioritized on clinical need, we
feel that this is unlikely to have introduced a significant
amount of bias.
Although cigarette smoking is the principle risk factor for
COPD, occupational factors are thought to contribute to
disease amongst non-smokers or magnify the influence of
smoking on individuals who smoke. A large population
based survey estimated that the fraction of COPD attrib-
utable to work was 19.2% overall and 31.1% among never
smokers.21 Seven (11.7%) of the subjects identified as
having AO in this study had never smoked. We did not
collect any data on occupational exposures as part of this
study and therefore cannot exclude this as a contributing
factor in some of the subjects.
Of the eighty-five subjects found to have abnormal
spirometry in this study, sixty-eight (80%) had no previous
diagnosis of asthma or COPD. This finding is important as
identifying lung disease such as COPD allows interventions to
slow the rate of disease progression to be initiated, such asno diagnosed IHD.
No IHD p Value for c2 test
e 151 (47.6%) male 0.001
171 (54.3%) 0.078
135 (42.9%) 0.387
115(36.6%) 0.302
82 (26.1%) 0.628
61 (19.21%) 0.267
No IHD p Value for t-test
54.4 (53.0e55.7) <0.001
2.6 (2.5e2.8) 0.709
93.6 (91.6e95.5) 0.326
98.7 (96.9e100.4) 0.217
78.1 (77.1e79.0) 0.014
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based studies indicate that there is a link between COPD and
reduced lung function, and risk of cardiovascular disease22e
25 and future cardiovascular mortality.26e35 The participants
of this study were relatively young, hence avoidance of risk
factors in this group of patients could improve their prog-
nosis, in terms of both lung and cardiovascular disease. The
measurement of spirometry in patients attending healthcare
clinics such as this would be an ideal opportunity to detect
abnormalities in lung function that may otherwise be
missed, and would be particularly valuable for those
patients with a significant smoking history.
This study suggests that airflow obstruction may be an
important alternative differential diagnosis in patients
referred to a secondary care chest pain clinic. Further-
more, the identification of abnormal spirometry provides
additional prognostic information which may help to better
risk-stratify patients for future cardiovascular events and
allow interventions to be instituted. However, the patient
selection in this study is unusual in comparison to studies of
COPD prevalence in other countries due to the nature of
this clinic service.
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